{ "run": { "id": "cmnr14mfj0570p658td3hgyix", "region": "US", "assetId": "cmnr14me2056wp658b0hb2vgh", "ticker": "MRNA", "snapshotId": "cmnr14mer056yp6589lnxyfct", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:21:25.900Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr14mer056yp6589lnxyfct", "assetId": "cmnr14me2056wp658b0hb2vgh", "asOf": "2026-04-08T20:00:02.000Z", "snapshot": { "asOf": "2026-04-08T20:00:02.000Z", "quote": { "asOf": "2026-04-08T20:00:02.000Z", "open": null, "price": 52.1, "dayLow": 50.545, "volume": 4807576, "dayHigh": 52.39, "currency": "USD", "prevClose": 50.11, "week52Low": 22.28, "week52High": 59.55 }, "fundamentals": { "pe": -4.06198347107438, "beta": 1.24368487968286, "epsTTM": -7.26, "fcfTTM": null, "growth": { "epsYoy": 0.2176724137931034, "revenueYoy": -0.3992583436341162 }, "sector": "Biological Products, (No Diagnostic Substances)", "margins": { "net": -1.45164609053498, "gross": null, "operating": -1.581275720164609 }, "website": "http://modernatx.com", "industry": "Biotechnology", "pegRatio": 0.186609933720645, "ebitdaTTM": -2585000000, "forwardPe": -4.42128935532234, "marketCap": 9900000000, "totalCash": 2595000000, "totalDebt": 590000000, "debtEquity": 0.0682080924855491, "quickRatio": 3.011071967790639, "revenueTTM": 1944000000, "companyName": "Moderna, Inc.", "priceToBook": 1.32619768786127, "currentRatio": 3.293407146451937, "dividendYield": null, "returnOnAssets": -0.2287242664937591, "returnOnEquity": -0.326242774566474, "analystOpinions": null, "businessSummary": "Moderna, Inc. (/məˈdɜːrnə/ mə-DUR-nə) is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms \"modified\", \"RNA\", and \"modern\".", "enterpriseValue": 9466610000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 4800, "sharesOutstanding": 394939424, "enterpriseToEbitda": -3.662131528046422, "analystTargetMedian": null, "enterpriseToRevenue": 4.869655349794239, "operatingCashflowTTM": -1873000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:21:25.875Z" }, "results": [ { "id": "cmnr14mfl0572p658gsgwjcfu", "runId": "cmnr14mfj0570p658td3hgyix", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Equity Research Model v1.0\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"MRNA\",\"currency\":\"USD\",\"current_price\":52.1,\"target_price_6m\":49.5,\"target_price_12m\":50.5,\"recommendation\":\"HOLD\",\"confidence\":0.45,\"thesis_bullets\":[\"COVID vaccine revenue declining sharply; -40% YoY with further headwinds ahead\",\"Pipeline diversification into RSV, flu-COVID combo, and oncology offers long-term upside\",\"Significant cash burn of ~$1.9B/yr operating outflow threatens runway within 2 years\",\"Net cash position of ~$2B provides near-term liquidity buffer\",\"Valuation at ~4.9x EV/Revenue already reflects deep pessimism but losses persist\"],\"key_drivers\":[{\"driver\":\"COVID vaccine demand trajectory\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"RSV vaccine (mRESVIA) commercial uptake\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Flu-COVID combination vaccine trial outcomes\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Operating cash burn rate and cost reduction progress\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Oncology pipeline with Merck (individualized neoantigen therapy)\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Competition from GSK, Pfizer in respiratory vaccines\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Potential need for dilutive capital raise\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Regulatory approvals for next-gen pipeline candidates\",\"impact\":\"MED\",\"direction\":\"POS\"}],\"risks\":[\"Cash runway exhaustion if burn rate does not significantly improve by 2027\",\"Pipeline clinical trial failures could eliminate key revenue catalysts\",\"Intensifying competition in respiratory vaccines erodes pricing power\",\"Dilutive equity raise or unfavorable debt terms if capital markets tighten\",\"Seasonal and pandemic-dependent demand creates highly volatile revenue\"],\"assumptions\":{\"revenue_cagr_3y\":0.08,\"ebit_margin_target\":-0.25,\"wacc\":0.12,\"terminal_multiple\":3.0},\"scenarios\":{\"bear\":{\"target_price\":30,\"prob\":0.3,\"notes\":\"Pipeline setbacks force dilutive raise; revenue stagnates below $2B.\"},\"base\":{\"target_price\":50,\"prob\":0.45,\"notes\":\"Modest pipeline progress; losses narrow but profitability remains distant.\"},\"bull\":{\"target_price\":80,\"prob\":0.25,\"notes\":\"Combo vaccines and oncology deliver, revenue inflects above $4B by 2028.\"}},\"method_notes\":\"Blended EV/Revenue and probability-weighted scenario analysis. Base case ~3x forward revenue on ~$1.8B est. revenue + net cash. Deeply negative margins and declining COVID revenue offset by pipeline optionality. High uncertainty → low confidence HOLD. Expected 12M return ~-3%, within HOLD band. Sell-side consensus noted but not used as numeric input. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Equity Research Model v1.0", "risks": [ "Cash runway exhaustion if burn rate does not significantly improve by 2027", "Pipeline clinical trial failures could eliminate key revenue catalysts", "Intensifying competition in respiratory vaccines erodes pricing power", "Dilutive equity raise or unfavorable debt terms if capital markets tighten", "Seasonal and pandemic-dependent demand creates highly volatile revenue" ], "ticker": "MRNA", "currency": "USD", "scenarios": { "base": { "prob": 0.45, "notes": "Modest pipeline progress; losses narrow but profitability remains distant.", "target_price": 50 }, "bear": { "prob": 0.3, "notes": "Pipeline setbacks force dilutive raise; revenue stagnates below $2B.", "target_price": 30 }, "bull": { "prob": 0.25, "notes": "Combo vaccines and oncology deliver, revenue inflects above $4B by 2028.", "target_price": 80 } }, "confidence": 0.45, "assumptions": { "wacc": 0.12, "revenue_cagr_3y": 0.08, "terminal_multiple": 3, "ebit_margin_target": -0.25 }, "key_drivers": [ { "driver": "COVID vaccine demand trajectory", "impact": "HIGH", "direction": "NEG" }, { "driver": "RSV vaccine (mRESVIA) commercial uptake", "impact": "HIGH", "direction": "POS" }, { "driver": "Flu-COVID combination vaccine trial outcomes", "impact": "HIGH", "direction": "POS" }, { "driver": "Operating cash burn rate and cost reduction progress", "impact": "HIGH", "direction": "NEG" }, { "driver": "Oncology pipeline with Merck (individualized neoantigen therapy)", "impact": "MED", "direction": "POS" }, { "driver": "Competition from GSK, Pfizer in respiratory vaccines", "impact": "MED", "direction": "NEG" }, { "driver": "Potential need for dilutive capital raise", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory approvals for next-gen pipeline candidates", "impact": "MED", "direction": "POS" } ], "method_notes": "Blended EV/Revenue and probability-weighted scenario analysis. Base case ~3x forward revenue on ~$1.8B est. revenue + net cash. Deeply negative margins and declining COVID revenue offset by pipeline optionality. High uncertainty → low confidence HOLD. Expected 12M return ~-3%, within HOLD band. Sell-side consensus noted but not used as numeric input. Not investment advice.", "current_price": 52.1, "recommendation": "HOLD", "thesis_bullets": [ "COVID vaccine revenue declining sharply; -40% YoY with further headwinds ahead", "Pipeline diversification into RSV, flu-COVID combo, and oncology offers long-term upside", "Significant cash burn of ~$1.9B/yr operating outflow threatens runway within 2 years", "Net cash position of ~$2B provides near-term liquidity buffer", "Valuation at ~4.9x EV/Revenue already reflects deep pessimism but losses persist" ], "target_price_6m": 49.5, "target_price_12m": 50.5 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 43457, "createdAt": "2026-04-09T05:21:25.900Z", "usage": { "inputTokens": 3600, "outputTokens": 1927, "costUsd": 0.066175 } }, { "id": "cmnr14mfl0575p658ak8slkhk", "runId": "cmnr14mfj0570p658td3hgyix", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Proprietary DCF Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"MRNA\",\n \"currency\": \"USD\",\n \"current_price\": 52.1,\n \"target_price_6m\": 53.0,\n \"target_price_12m\": 54.0,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\n \"mRNA platform offers long-term potential beyond COVID-19.\",\n \"Near-term revenue decline poses significant challenges.\",\n \"Strong balance sheet with net cash position supports resilience.\",\n \"Pipeline advancements could drive future growth if successful.\",\n \"Valuation reflects balanced risk-reward at current levels.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Pipeline progress in oncology vaccines\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"COVID-19 vaccine demand stabilization\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Regulatory approvals for new products\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Competition in mRNA technology space\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Execution on cost management and efficiency\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Macroeconomic factors affecting biotech funding\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n { \"driver\": \"Partnership and collaboration developments\", \"impact\": \"MED\", \"direction\": \"POS\" }\n ],\n \"risks\": [\n \"Clinical trial failures for pipeline candidates.\",\n \"Revenue concentration risk from legacy products.\",\n \"Intellectual property disputes or challenges.\",\n \"Market sentiment shifts impacting valuation multiples.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.10,\n \"ebit_margin_target\": 0.15,\n \"wacc\": 0.10,\n \"terminal_multiple\": 6.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 40.0, \"prob\": 0.3, \"notes\": \"Pipeline setbacks and lower vaccine demand.\" },\n \"base\": { \"target_price\": 54.0, \"prob\": 0.5, \"notes\": \"Moderate growth and steady pipeline progress.\" },\n \"bull\": { \"target_price\": 70.0, \"prob\": 0.2, \"notes\": \"Successful new launches and higher adoption rates.\" }\n },\n \"method_notes\": \"Valuation via DCF with 10% revenue CAGR, 15% EBIT margin, 10% WACC, 6x terminal EV/Revenue. HOLD due to -3.65% to +34.2% return range and mixed evidence. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "Proprietary DCF Model", "risks": [ "Clinical trial failures for pipeline candidates.", "Revenue concentration risk from legacy products.", "Intellectual property disputes or challenges.", "Market sentiment shifts impacting valuation multiples." ], "ticker": "MRNA", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Moderate growth and steady pipeline progress.", "target_price": 54 }, "bear": { "prob": 0.3, "notes": "Pipeline setbacks and lower vaccine demand.", "target_price": 40 }, "bull": { "prob": 0.2, "notes": "Successful new launches and higher adoption rates.", "target_price": 70 } }, "confidence": 0.6, "assumptions": { "wacc": 0.1, "revenue_cagr_3y": 0.1, "terminal_multiple": 6, "ebit_margin_target": 0.15 }, "key_drivers": [ { "driver": "Pipeline progress in oncology vaccines", "impact": "HIGH", "direction": "POS" }, { "driver": "COVID-19 vaccine demand stabilization", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory approvals for new products", "impact": "HIGH", "direction": "POS" }, { "driver": "Competition in mRNA technology space", "impact": "MED", "direction": "NEG" }, { "driver": "Execution on cost management and efficiency", "impact": "MED", "direction": "POS" }, { "driver": "Macroeconomic factors affecting biotech funding", "impact": "LOW", "direction": "NEG" }, { "driver": "Partnership and collaboration developments", "impact": "MED", "direction": "POS" } ], "method_notes": "Valuation via DCF with 10% revenue CAGR, 15% EBIT margin, 10% WACC, 6x terminal EV/Revenue. HOLD due to -3.65% to +34.2% return range and mixed evidence. Not investment advice.", "current_price": 52.1, "recommendation": "HOLD", "thesis_bullets": [ "mRNA platform offers long-term potential beyond COVID-19.", "Near-term revenue decline poses significant challenges.", "Strong balance sheet with net cash position supports resilience.", "Pipeline advancements could drive future growth if successful.", "Valuation reflects balanced risk-reward at current levels." ], "target_price_6m": 53, "target_price_12m": 54 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 393, "createdAt": "2026-04-09T05:21:25.900Z", "usage": { "inputTokens": 2109, "outputTokens": 3723, "costUsd": 0.002154 } }, { "id": "cmnr14mfl0573p65896s76yah", "runId": "cmnr14mfj0570p658td3hgyix", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Analyst\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"MRNA\",\n \"currency\": \"USD\",\n \"current_price\": 52.1,\n \"target_price_6m\": 56.0,\n \"target_price_12m\": 61.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"mRNA platform validation extends beyond COVID with promising RSV and individualized neoantigen therapy data.\",\n \"Enterprise value of $9.5B is attractive given the late-stage pipeline and long-term platform optionality.\",\n \"Near-term cash burn remains high, but cost-cutting measures are beginning to narrow EPS losses.\",\n \"Commercial execution in RSV and flu faces stiff competition from established incumbents like GSK.\",\n \"Cash runway of $2.6B provides roughly 12-18 months before potential financing needs arise.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"RSV vaccine (mRESVIA) market share\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Flu/COVID combo vaccine approval\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Operating cash burn rate\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"INT (mRNA-4157) Phase 3 trial progress\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"R&D restructuring and cost cuts\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Endemic COVID vaccine pricing\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Higher-than-expected cash burn leading to dilutive equity raises.\",\n \"Failure to capture meaningful RSV market share against entrenched competitors.\",\n \"Clinical setbacks in the CMV or INT (oncology) late-stage pipelines.\",\n \"Faster-than-anticipated decline in endemic COVID-19 vaccine revenues.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.15,\n \"ebit_margin_target\": 0.25,\n \"wacc\": 0.11,\n \"terminal_multiple\": 15.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 35.0,\n \"prob\": 0.3,\n \"notes\": \"Pipeline delays and severe cash burn force highly dilutive capital raises.\"\n },\n \"base\": {\n \"target_price\": 61.0,\n \"prob\": 0.5,\n \"notes\": \"Successful RSV/Flu combo launches and stabilized cash burn support platform valuation.\"\n },\n \"bull\": {\n \"target_price\": 85.0,\n \"prob\": 0.2,\n \"notes\": \"Blockbuster efficacy in oncology (INT) and CMV drives massive multiple expansion.\"\n }\n },\n \"method_notes\": \"Valuation based on a sum-of-the-parts EV/Peak Sales multiple for the late-stage pipeline (RSV, Flu, CMV, INT), discounted at 11% WACC. The BUY rating reflects a 17% upside to our $61 target, balancing platform optionality against near-term cash burn risks. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Equity Analyst", "risks": [ "Higher-than-expected cash burn leading to dilutive equity raises.", "Failure to capture meaningful RSV market share against entrenched competitors.", "Clinical setbacks in the CMV or INT (oncology) late-stage pipelines.", "Faster-than-anticipated decline in endemic COVID-19 vaccine revenues." ], "ticker": "MRNA", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Successful RSV/Flu combo launches and stabilized cash burn support platform valuation.", "target_price": 61 }, "bear": { "prob": 0.3, "notes": "Pipeline delays and severe cash burn force highly dilutive capital raises.", "target_price": 35 }, "bull": { "prob": 0.2, "notes": "Blockbuster efficacy in oncology (INT) and CMV drives massive multiple expansion.", "target_price": 85 } }, "confidence": 0.65, "assumptions": { "wacc": 0.11, "revenue_cagr_3y": 0.15, "terminal_multiple": 15, "ebit_margin_target": 0.25 }, "key_drivers": [ { "driver": "RSV vaccine (mRESVIA) market share", "impact": "HIGH", "direction": "POS" }, { "driver": "Flu/COVID combo vaccine approval", "impact": "HIGH", "direction": "POS" }, { "driver": "Operating cash burn rate", "impact": "HIGH", "direction": "NEG" }, { "driver": "INT (mRNA-4157) Phase 3 trial progress", "impact": "MED", "direction": "POS" }, { "driver": "R&D restructuring and cost cuts", "impact": "MED", "direction": "POS" }, { "driver": "Endemic COVID vaccine pricing", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Valuation based on a sum-of-the-parts EV/Peak Sales multiple for the late-stage pipeline (RSV, Flu, CMV, INT), discounted at 11% WACC. The BUY rating reflects a 17% upside to our $61 target, balancing platform optionality against near-term cash burn risks. Not investment advice.", "current_price": 52.1, "recommendation": "BUY", "thesis_bullets": [ "mRNA platform validation extends beyond COVID with promising RSV and individualized neoantigen therapy data.", "Enterprise value of $9.5B is attractive given the late-stage pipeline and long-term platform optionality.", "Near-term cash burn remains high, but cost-cutting measures are beginning to narrow EPS losses.", "Commercial execution in RSV and flu faces stiff competition from established incumbents like GSK.", "Cash runway of $2.6B provides roughly 12-18 months before potential financing needs arise." ], "target_price_6m": 56, "target_price_12m": 61 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 38136, "createdAt": "2026-04-09T05:21:25.900Z", "usage": { "inputTokens": 2432, "outputTokens": 879, "costUsd": 0.015412 } }, { "id": "cmnr14mfl0571p658a2vwge4n", "runId": "cmnr14mfj0570p658td3hgyix", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"MRNA\",\"currency\":\"USD\",\"current_price\":52.1,\"target_price_6m\":46,\"target_price_12m\":43,\"recommendation\":\"SELL\",\"confidence\":0.61,\"thesis_bullets\":[\"COVID franchise remains structurally smaller, pressuring revenue visibility.\",\"Large cash balance buys time but not indefinite runway.\",\"Pipeline optionality is real across CMV, respiratory, and oncology.\",\"Current valuation still discounts meaningful pipeline success despite heavy losses.\",\"Execution, regulatory timing, and manufacturing leverage remain key overhangs.\"],\"key_drivers\":[{\"driver\":\"COVID sales trajectory\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"CMV filing or approval timing\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Respiratory combo data\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Oncology proof-of-concept\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Cash burn pace\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Operating expense discipline\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Competitive vaccine pricing\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Regulatory setbacks\",\"impact\":\"HIGH\",\"direction\":\"NEG\"}],\"risks\":[\"Faster-than-expected CMV or RSV commercialization.\",\"COVID demand stabilizes above bearish expectations.\",\"Oncology data meaningfully rerates platform value.\",\"Cost cuts reduce cash burn faster than modeled.\",\"Business development or M&A creates upside optionality.\"],\"assumptions\":{\"revenue_cagr_3y\":0.16,\"ebit_margin_target\":0.12,\"wacc\":0.13,\"terminal_multiple\":4.5},\"scenarios\":{\"bear\":{\"target_price\":30,\"prob\":0.3,\"notes\":\"COVID erosion persists and pipeline launches slip.\"},\"base\":{\"target_price\":43,\"prob\":0.5,\"notes\":\"Cash burn moderates, but commercialization remains gradual.\"},\"bull\":{\"target_price\":68,\"prob\":0.2,\"notes\":\"CMV and respiratory pipeline validate faster than expected.\"}},\"method_notes\":\"Scenario-based valuation using snapshot quote/fundamentals, cash runway, pipeline milestones, and normalized EV/sales-to-earnings bridge; no sell-side targets used. Snapshot marketCap and sharesOutstanding appear inconsistent with price, so quote fields were kept authoritative and valuation stayed range-based. 12M downside supports SELL; not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Model Recommendation", "risks": [ "Faster-than-expected CMV or RSV commercialization.", "COVID demand stabilizes above bearish expectations.", "Oncology data meaningfully rerates platform value.", "Cost cuts reduce cash burn faster than modeled.", "Business development or M&A creates upside optionality." ], "ticker": "MRNA", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Cash burn moderates, but commercialization remains gradual.", "target_price": 43 }, "bear": { "prob": 0.3, "notes": "COVID erosion persists and pipeline launches slip.", "target_price": 30 }, "bull": { "prob": 0.2, "notes": "CMV and respiratory pipeline validate faster than expected.", "target_price": 68 } }, "confidence": 0.61, "assumptions": { "wacc": 0.13, "revenue_cagr_3y": 0.16, "terminal_multiple": 4.5, "ebit_margin_target": 0.12 }, "key_drivers": [ { "driver": "COVID sales trajectory", "impact": "HIGH", "direction": "NEG" }, { "driver": "CMV filing or approval timing", "impact": "HIGH", "direction": "POS" }, { "driver": "Respiratory combo data", "impact": "MED", "direction": "POS" }, { "driver": "Oncology proof-of-concept", "impact": "MED", "direction": "POS" }, { "driver": "Cash burn pace", "impact": "HIGH", "direction": "NEG" }, { "driver": "Operating expense discipline", "impact": "HIGH", "direction": "POS" }, { "driver": "Competitive vaccine pricing", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory setbacks", "impact": "HIGH", "direction": "NEG" } ], "method_notes": "Scenario-based valuation using snapshot quote/fundamentals, cash runway, pipeline milestones, and normalized EV/sales-to-earnings bridge; no sell-side targets used. Snapshot marketCap and sharesOutstanding appear inconsistent with price, so quote fields were kept authoritative and valuation stayed range-based. 12M downside supports SELL; not investment advice.", "current_price": 52.1, "recommendation": "SELL", "thesis_bullets": [ "COVID franchise remains structurally smaller, pressuring revenue visibility.", "Large cash balance buys time but not indefinite runway.", "Pipeline optionality is real across CMV, respiratory, and oncology.", "Current valuation still discounts meaningful pipeline success despite heavy losses.", "Execution, regulatory timing, and manufacturing leverage remain key overhangs." ], "target_price_6m": 46, "target_price_12m": 43 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_0c4ce7f30ac927770069d75b782180819692365d962aeb7c5c", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 47901, "createdAt": "2026-04-09T05:21:25.900Z", "usage": { "inputTokens": 2384, "outputTokens": 2756, "costUsd": 0.042756 } }, { "id": "cmnr14mfl0574p658qvm4kfv6", "runId": "cmnr14mfj0570p658td3hgyix", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"MRNA\",\n \"currency\": \"USD\",\n \"current_price\": 52.1,\n \"target_price_6m\": 57,\n \"target_price_12m\": 63,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.57,\n \"thesis_bullets\": [\n \"mRNA platform advancing in oncology indications\",\n \"Cash reserves fund R&D despite current losses\",\n \"Revenue decline stabilizing with new launches\",\n \"Clinical and regulatory risks remain elevated\",\n \"Valuation offers upside on pipeline success\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Oncology pipeline progress\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"New vaccine product launches\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Revenue diversification success\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Clinical trial outcomes\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Competition in mRNA vaccines\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Path to EBIT profitability\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Regulatory approval delays\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Failed late-stage clinical trials\",\n \"Persistent COVID revenue erosion\",\n \"Intense biotech competition\",\n \"Regulatory setbacks for new assets\",\n \"High cash burn rate\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.22,\n \"ebit_margin_target\": 0.25,\n \"wacc\": 0.115,\n \"terminal_multiple\": 16\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 32,\n \"prob\": 0.35,\n \"notes\": \"Multiple trial failures and sales weakness.\"\n },\n \"base\": {\n \"target_price\": 63,\n \"prob\": 0.45,\n \"notes\": \"Steady pipeline progress and revenue recovery.\"\n },\n \"bull\": {\n \"target_price\": 95,\n \"prob\": 0.2,\n \"notes\": \"Successful launches drive blockbuster sales.\"\n }\n },\n \"method_notes\": \"DCF using revenue CAGR, target EBIT margin, WACC and terminal multiple. BUY reflects ~21% base upside with balanced pipeline risks. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Equity Research Model", "risks": [ "Failed late-stage clinical trials", "Persistent COVID revenue erosion", "Intense biotech competition", "Regulatory setbacks for new assets", "High cash burn rate" ], "ticker": "MRNA", "currency": "USD", "scenarios": { "base": { "prob": 0.45, "notes": "Steady pipeline progress and revenue recovery.", "target_price": 63 }, "bear": { "prob": 0.35, "notes": "Multiple trial failures and sales weakness.", "target_price": 32 }, "bull": { "prob": 0.2, "notes": "Successful launches drive blockbuster sales.", "target_price": 95 } }, "confidence": 0.57, "assumptions": { "wacc": 0.115, "revenue_cagr_3y": 0.22, "terminal_multiple": 16, "ebit_margin_target": 0.25 }, "key_drivers": [ { "driver": "Oncology pipeline progress", "impact": "HIGH", "direction": "POS" }, { "driver": "New vaccine product launches", "impact": "HIGH", "direction": "POS" }, { "driver": "Revenue diversification success", "impact": "MED", "direction": "POS" }, { "driver": "Clinical trial outcomes", "impact": "HIGH", "direction": "POS" }, { "driver": "Competition in mRNA vaccines", "impact": "MED", "direction": "NEG" }, { "driver": "Path to EBIT profitability", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory approval delays", "impact": "MED", "direction": "NEG" } ], "method_notes": "DCF using revenue CAGR, target EBIT margin, WACC and terminal multiple. BUY reflects ~21% base upside with balanced pipeline risks. Not investment advice.", "current_price": 52.1, "recommendation": "BUY", "thesis_bullets": [ "mRNA platform advancing in oncology indications", "Cash reserves fund R&D despite current losses", "Revenue decline stabilizing with new launches", "Clinical and regulatory risks remain elevated", "Valuation offers upside on pipeline success" ], "target_price_6m": 57, "target_price_12m": 63 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "b1e6e241-c416-937f-8798-cd905cc55e66", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 23242, "createdAt": "2026-04-09T05:21:25.900Z", "usage": { "inputTokens": 2722, "outputTokens": 3893, "costUsd": 0.066561 } } ] } }